Payment overview · 2025
General Payments
$506.44
21 reported records · 13 companies
Healthcare provider profile · identity verified
Gary G Sauer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MC KEES ROCKS, PA · NPI 1619969672
Verified facts
What the public records show
CMS Open Payments records show Gary G Sauer, M.D. received $506.44 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.16 | 22.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.57 | 15.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.43 | 12.9% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $38.17 | 7.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $37.23 | 7.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.12 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.66 | 5.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.58 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.08 | 4.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.84 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.79 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.45 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $506.44 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.69 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.57 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.81 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $37.23 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $37.23 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
70 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 993 | 265 |
| Amlodipine Besylate | Amlodipine Besylate | 513 | 138 |
| Losartan Potassium | Losartan Potassium | 478 | 130 |
| Lisinopril | Lisinopril | 473 | 130 |
| Omeprazole | Omeprazole | 466 | 117 |
| Metformin Hcl | Metformin Hcl | 429 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 102 |
| Gabapentin | Gabapentin | 404 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 345 | 93 |
| Furosemide | Furosemide | 292 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 70 |
| Sertraline Hcl | Sertraline Hcl | 279 | 66 |
| Potassium Chloride | Potassium Chloride | 261 | 64 |
| Simvastatin | Simvastatin | 250 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 63 |
| Eliquis | Apixaban | 233 | 58 |
| Jardiance | Empagliflozin | 222 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 53 |
| Atenolol | Atenolol | 195 | 48 |
| Famotidine | Famotidine | 186 | 53 |
| Prednisone | Prednisone | 182 | 95 |
| Alendronate Sodium | Alendronate Sodium | 176 | 54 |
| Celecoxib | Celecoxib | 150 | 41 |
| Montelukast Sodium | Montelukast Sodium | 142 | 42 |
| Xarelto | Rivaroxaban | 140 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 58 |
| Meloxicam | Meloxicam | 133 | 42 |
| Glipizide | Glipizide | 132 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 30 |
| Carvedilol | Carvedilol | 125 | 37 |
| Finasteride | Finasteride | 125 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 121 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 19 |
| Allopurinol | Allopurinol | 115 | 34 |
| Cefuroxime | Cefuroxime Axetil | 111 | 96 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 25 |
| Trazodone Hcl | Trazodone Hcl | 107 | 28 |
| Ibuprofen | Ibuprofen | 101 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 28 |
| Synthroid | Levothyroxine Sodium | 90 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 28 |
| Ozempic | Semaglutide | 84 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 16 |
| Spironolactone | Spironolactone | 77 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 19 |
| Myrbetriq | Mirabegron | 74 | 15 |
| Ezetimibe | Ezetimibe | 72 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 20 |
| Amoxicillin | Amoxicillin | 71 | 50 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 70 | 51 |
| Donepezil Hcl | Donepezil Hcl | 69 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Trulicity | Dulaglutide | 66 | 13 |
| Clonazepam | Clonazepam | 64 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 13 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Mirtazapine | Mirtazapine | 61 | 18 |
| Pregabalin | Pregabalin | 61 | 17 |
| Lorazepam | Lorazepam | 56 | 17 |
| Alprazolam | Alprazolam | 54 | 16 |
| Valsartan | Valsartan | 54 | 18 |
| Azithromycin | Azithromycin | 53 | 50 |
| Entresto | Sacubitril/Valsartan | 53 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 14 |
| Tramadol Hcl | Tramadol Hcl | 42 | 18 |
| Irbesartan | Irbesartan | 41 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Ibu | Ibuprofen | 38 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 19 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 14 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Ketoconazole | Ketoconazole | 30 | 19 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 18 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 17 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Metronidazole | Metronidazole | 19 | 12 |
| Etodolac | Etodolac | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Thiothixene | Thiothixene | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $506.44 · 21 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error